Figure 6.

Silencing of MCL1 enhances the antitumor effects of ABT-263. A. Western immunoblotting analysis of MCL1 protein levels in RBE and HCCC9810 cells transfected with siRNA for 48 h. Data shown represents 2 independent experiments. B. RBE and HCCC9810 cells were transfected with control siRNA or MCL1 siRNA for 48 h and then treated with ABT-263 at indicated concentrations for 48 h. Cell viability was determined by CCK-8 assay. Cell apoptosis was measured by Annexin V-FITC/PI staining followed by flow cytometry. Quantitative analysis from 3 independent experiments (one-way ANOVA with a Turkey post hoc test; data are shown as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001) are shown.